BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VX-670 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of VX-670\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06185764-10843@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:VX-670: Phase 1/2 readout est. (NCT06185764)
DESCRIPTION:VX-670\, phase 1/2\, Myotonic Dystrophy Type 1.\nStudy: A Phase
  1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
 \nEstimated primary completion: 2 February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/vx-670#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06185764
URL:https://assetmemo.bio/drug/vx-670#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926621-10843@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20290130
DTEND;VALUE=DATE:20290131
SUMMARY:VX-670: Phase 2 readout est. (NCT06926621)
DESCRIPTION:VX-670\, phase 2\, Myotonic Dystrophy Type 1.\nStudy: A Study o
 f Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dy
 strophy Type I\nEstimated primary completion: 30 January 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/vx-670#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06926621
URL:https://assetmemo.bio/drug/vx-670#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
